肿瘤微环境
生物
免疫疗法
免疫监视
免疫系统
过继性细胞移植
癌症研究
癌症
癌症免疫疗法
免疫学
T细胞
遗传学
作者
Celia Martín-Otal,Flor Navarro,Noëlia Casares,Aritz Lasarte-Cía,Inés Sánchez-Moreno,Sandra Hervás‐Stubbs,Teresa Lozano,Juan José Lasarte
标识
DOI:10.1016/bs.ircmb.2022.03.002
摘要
Recent advances in immunotherapy have revolutionized the treatment of cancer. The use of adoptive cell therapies (ACT) such as those based on tumor infiltrating lymphocytes (TILs) or genetically modified cells (transgenic TCR lymphocytes or CAR-T cells), has shown impressive results in the treatment of several types of cancers. However, cancer cells can exploit mechanisms to escape from immunosurveillance resulting in many patients not responding to these therapies or respond only transiently. The failure of immunotherapy to achieve long-term tumor control is multifactorial. On the one hand, only a limited percentage of the transferred lymphocytes is capable of circulating through the bloodstream, interacting and crossing the tumor endothelium to infiltrate the tumor. Metabolic competition, excessive glucose consumption, the high level of lactic acid secretion and the extracellular pH acidification, the shortage of essential amino acids, the hypoxic conditions or the accumulation of fatty acids in the tumor microenvironment (TME), greatly hinder the anti-tumor activity of the immune cells in ACT therapy strategies. Therefore, there is a new trend in immunotherapy research that seeks to unravel the fundamental biology that underpins the response to therapy and identifies new approaches to better amplify the efficacy of immunotherapies. In this review we address important aspects that may significantly affect the efficacy of ACT, indicating also the therapeutic alternatives that are currently being implemented to overcome these drawbacks.
科研通智能强力驱动
Strongly Powered by AbleSci AI